LeMaitre Vascular Q3 Net Income Soars 56% on Strong Sales, ERC Boost

TL;DR

**LMAT is crushing it with sales and a huge tax credit, but watch out for future government clawbacks on those sweet, sweet refunds.**

AI Summary

LEMAITRE VASCULAR INC reported robust financial performance for the three and nine months ended September 30, 2025. Net sales increased by 11.3% to $61.046 million for the three months ended September 30, 2025, compared to $54.819 million in the prior year, and by 12.8% to $185.149 million for the nine months, up from $164.146 million. Net income saw a significant jump, rising 55.8% to $17.362 million for the quarter from $11.141 million, and 28.3% to $42.152 million for the nine-month period from $32.854 million. Basic earnings per share increased to $0.77 for the quarter and $1.86 for the nine months. The company recognized a $4.8 million Employee Retention Credit (ERC) refund in September 2025, with $4.1 million as a refund and $0.7 million in interest income, which positively impacted cost of sales and operating expenses. However, the 'One Big Beautiful Bill Act' (OBBBA), signed on July 4, 2025, eliminated ERC claims filed after January 31, 2024, for the period July 1, 2021, through September 30, 2021, leading the company not to recognize a $2.2 million credit for that period.

Why It Matters

This strong performance, particularly the 55.8% surge in net income, signals robust operational efficiency and market demand for LeMaitre Vascular's medical devices, which could attract growth-oriented investors. The significant cash infusion from the Employee Retention Credit (ERC) provides additional liquidity, potentially enabling further investment in R&D or strategic acquisitions, strengthening its competitive position against peers in the vascular surgery market. However, the legislative change impacting future ERC claims highlights regulatory risks that could affect other companies relying on similar government programs, creating uncertainty for investors in the broader healthcare sector. Employees and customers benefit from a financially healthy company that can continue to innovate and provide essential medical products.

Risk Assessment

Risk Level: medium — The company's risk level is medium due to the significant impact of the 'One Big Beautiful Bill Act' (OBBBA) on its Employee Retention Credit (ERC) claims. While LeMaitre Vascular received $4.8 million in ERC refunds for earlier periods, the OBBBA removed claims filed after January 31, 2024, for the period July 1, 2021, through September 30, 2021, leading the company not to recognize a $2.2 million credit. This legislative change introduces uncertainty regarding future government incentives and could impact other companies, indicating a broader regulatory risk.

Analyst Insight

Investors should closely monitor LeMaitre Vascular's future filings for any further impacts from the OBBBA or similar legislative changes, as these could affect profitability. While the current quarter shows strong growth, consider the sustainability of this growth without the one-time boost from the ERC. Investors should also evaluate the company's ability to maintain its competitive edge in the vascular surgery market through organic growth and innovation.

Financial Highlights

revenue

$61.046M

net Income

$17.362M

eps

$0.77

cash Position

$25.494M

revenue Growth

+11.3%

Revenue Breakdown

Key Numbers

• $61.046M — Net Sales (Q3 2025) (Increased 11.3% from $54.819M in Q3 2024)
• $17.362M — Net Income (Q3 2025) (Increased 55.8% from $11.141M in Q3 2024)
• $185.149M — Net Sales (9 months 2025) (Increased 12.8% from $164.146M in 9 months 2024)
• $42.152M — Net Income (9 months 2025) (Increased 28.3% from $32.854M in 9 months 2024)
• $0.77 — Basic EPS (Q3 2025) (Increased from $0.50 in Q3 2024)
• $4.8M — ERC Refunds Received (Received in September 2025, boosting Q3 results)
• $2.2M — ERC Credit Not Recognized (Due to OBBBA for July-Sept 2021 period)
• $25.494M — Cash and Cash Equivalents (As of September 30, 2025)
• $317.561M — Short-term Marketable Securities (As of September 30, 2025, up from $274.112M at Dec 31, 2024)
• $0.20 — Cash Dividends Declared per Common Share (Q3 2025) (Increased from $0.16 in Q3 2024)

Key Players & Entities

• LEMAITRE VASCULAR INC (company) — registrant
• Donald Trump (person) — President who signed OBBBA
• SEC (regulator) — Securities and Exchange Commission
• FASB (regulator) — Financial Accounting Standards Board
• $61.046 million (dollar_amount) — Net sales for three months ended September 30, 2025
• $17.362 million (dollar_amount) — Net income for three months ended September 30, 2025
• $4.8 million (dollar_amount) — Employee Retention Credit refunds received in September 2025
• $2.2 million (dollar_amount) — ERC credit not recognized due to OBBBA
• One Big Beautiful Bill Act (regulator) — Legislation impacting ERC claims
• The Nasdaq Global Market (company) — Exchange where LMAT is registered

FAQ

Risk Factors

• Changes in Tax Legislation (OBBBA) [medium — regulatory]: The 'One Big Beautiful Bill Act' (OBBBA) enacted on July 4, 2025, retroactively eliminated Employee Retention Credit (ERC) claims filed after January 31, 2024, for specific periods. This resulted in LEMAITRE VASCULAR INC not recognizing a $2.2 million credit for the July-September 2021 period, impacting potential financial benefits.
• Reliance on Key Products and Market Acceptance [medium — operational]: The company's success is dependent on the continued market acceptance and adoption of its existing product portfolio, particularly in the vascular device market. Failure to innovate or adapt to evolving medical practices could impact future sales growth.
• Competition in the Medical Device Industry [medium — market]: The medical device industry is highly competitive, with numerous established players and emerging companies. Intense competition could lead to pricing pressures, reduced market share, and increased R&D costs for LEMAITRE VASCULAR INC.
• Effective Tax Rate Fluctuations [low — financial]: The company's effective tax rate can be influenced by various factors, including changes in tax laws, the geographic mix of income, and the impact of discrete items such as the Employee Retention Credit. The $4.8 million ERC refund in Q3 2025 significantly boosted net income, but such one-time benefits are not sustainable.

Industry Context

LEMAITRE VASCULAR INC operates in the highly competitive medical device industry, specifically focusing on vascular devices. The sector is characterized by continuous innovation, stringent regulatory oversight, and the need for strong clinical evidence to support product adoption. Key trends include the development of minimally invasive technologies and increasing demand for specialized treatments in cardiovascular and peripheral vascular diseases.

Regulatory Implications

The recent enactment of the 'One Big Beautiful Bill Act' (OBBBA) highlights the dynamic nature of tax and economic legislation, which can have a direct and retroactive impact on a company's financial results. Companies must remain vigilant in monitoring legislative changes that could affect previously recognized or anticipated tax credits and benefits.

What Investors Should Do

1. Monitor the impact of the OBBBA on future tax strategies and potential claims.
2. Analyze the sustainability of net income growth beyond one-time ERC benefits.
3. Evaluate the company's competitive positioning and innovation pipeline.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported strong net sales growth of 11.3% to $61.046M and a significant net income increase of 55.8% to $17.362M, boosted by a $4.8M ERC refund.
• 2025-07-04: Enactment of 'One Big Beautiful Bill Act' (OBBBA) — This legislation retroactively impacted ERC claims, causing LEMAITRE VASCULAR INC to not recognize a $2.2M credit for the July-September 2021 period.
• 2025-09-30: Consolidated Balance Sheet Date — As of this date, the company held $25.494M in Cash and Cash Equivalents and $317.561M in Short-term Marketable Securities.

Glossary

Employee Retention Credit (ERC)

A refundable tax credit designed to encourage employers to keep employees on their payroll during the COVID-19 pandemic. (A $4.8 million refund positively impacted LEMAITRE VASCULAR INC's Q3 2025 results, but new legislation (OBBBA) prevented recognition of a $2.2 million credit.)

'One Big Beautiful Bill Act' (OBBBA)

A hypothetical piece of legislation enacted on July 4, 2025, that altered the eligibility and filing deadlines for the Employee Retention Credit. (This act directly impacted LEMAITRE VASCULAR INC's ability to claim a $2.2 million ERC credit for a prior period.)

Basic Earnings Per Share (EPS)

The net income attributable to each share of common stock outstanding during a period, calculated using the weighted-average number of shares outstanding. (LEMAITRE VASCULAR INC reported basic EPS of $0.77 for Q3 2025, an increase from the prior year, reflecting improved profitability.)

Net Sales

The total revenue generated from the sale of goods or services, net of returns, allowances, and discounts. (LEMAITRE VASCULAR INC demonstrated strong net sales growth of 11.3% in Q3 2025 and 12.8% year-to-date, indicating robust demand for its products.)

Year-Over-Year Comparison

LEMAITRE VASCULAR INC has shown significant year-over-year improvement in its financial performance. Net sales for the third quarter of 2025 increased by 11.3% to $61.046 million, and net income surged by 55.8% to $17.362 million, largely due to a $4.8 million Employee Retention Credit refund. This contrasts with the prior year's performance, indicating strong operational execution and a beneficial one-time financial event. However, the company also faced a regulatory headwind with the 'One Big Beautiful Bill Act' preventing the recognition of a $2.2 million ERC credit.

Key Financial Figures

• $0.01 — e on which registered Common stock, $0.01 par value per share LMAT The Nasdaq

Filing Documents

• ck0001158895-20250930.htm (10-Q) — 2951KB
• ck0001158895-ex31_1.htm (EX-31.1) — 16KB
• ck0001158895-ex31_2.htm (EX-31.2) — 16KB
• ck0001158895-ex32_1.htm (EX-32.1) — 12KB
• ck0001158895-ex32_2.htm (EX-32.2) — 12KB
• 0001193125-25-270981.txt ( ) — 10555KB
• ck0001158895-20250930.xsd (EX-101.SCH) — 938KB
• ck0001158895-20250930_htm.xml (XML) — 2254KB

Financial Statements

Financial Statements 1 Consolidated Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024 1 Unaudited Consolidated Statements of Operations for the three-month and nine-month periods ended September 30, 2025 and 2024 2 Unaudited Consolidated Statements of Comprehensive Income for the three-month and nine-month periods ended September 30, 2025 and 2024 3 Unaudited Consolidated Statements of Stockholders' Equity for the three-month and nine-month periods ended September 30, 2025 and 2024 4 Unaudited Consolidated Statements of Cash Flows for the nine-month periods ended September 30, 2025 and 2024 6 Notes to Unaudited Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3. Quantitative and Qualitative Disclosure about Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29 Part II. Other Information: 30 Item 1.

Legal Proceedings

Legal Proceedings 30 Item 1A.

Risk Factors

Risk Factors 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 31 Item 5. Other Information 31 Item 6. Exhibits 32

Financ ial Information

Part I. Financ ial Information

Financ ial Statements

Item 1. Financ ial Statements LeMaitre Vascular, Inc. Consolidated Ba lance Sheets (unaudited) September 30, December 31, 2025 2024 (in thousands, except share data) Assets Current assets: Cash and cash equivalents $ 25,494 $ 25,610 Short-term marketable securities 317,561 274,112 Accounts receivable, net of allowances of $ 1,442 at September 30, 2025 and $ 1,369 at December 31, 2024 32,416 30,063 Inventory and other deferred costs 70,793 64,927 Prepaid expenses and other current assets 5,761 7,480 Total current assets 452,025 402,192 Property and equipment, net 26,464 24,800 Right-of-use leased assets 16,040 16,768 Goodwill 65,945 65,945 Other intangibles, net 31,711 35,819 Deferred tax assets 854 1,425 Other assets 5,030 4,868 Total assets $ 598,069 $ 551,817 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 3,465 $ 1,761 Accrued expenses 26,933 24,732 Acquisition-related obligations 95 1,433 Lease liabilities - short-term 2,794 2,681 Total current liabilities 33,287 30,607 Convertible senior notes, net 168,424 167,772 Lease liabilities - long-term 14,414 15,232 Deferred tax liabilities 2,088 85 Other long-term liabilities 933 831 Total liabilities 219,146 214,527 Stockholders' equity: Preferred stock, $ 0.01 par value; authorized 3,000,000 shares; none outstanding — — Common stock, $ 0.01 par value; authorized 37,000,000 shares; issued 24,291,446 shares at September 30, 2025, and 24,153,165 shares at December 31, 2024 243 242 Additional paid-in capital 224,145 213,760 Retained earnings 173,670 145,090 Accumulated other comprehensive loss ( 2,912 ) ( 6,184 ) Treasury stock, at cost; 1,609,942 shares at September 30, 2025 and 1,603,825 shares at December 31, 2024 ( 16,223 ) ( 15,618 ) Total stockholders' equity 378,92

View Full Filing

View this 10-Q filing on SEC EDGAR